Screening in female patients for HPV and STI for early diagnosis of cervical cancer
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20234084Keywords:
Cervical cancer, High-risk human papillomaviruses, Sexually transmitted infectionsAbstract
Background: High-risk human papillomaviruses (HPV) infection has been the most common sexually transmitted infection worldwide. Moreover, it is a necessary factor for the development of cervical cancer. Several studies have been carried out that screen HPV and other sexually transmitted infections (STI)s occurring in patients at the same time. Timely screening can help early diagnosis of pre-cancerous lesions and assist in prompt treatment to reduce mortality in such patients. The objective of the present study was to screen women for the presence of high-risk HPV (hrHPV) for the early diagnosis of cervical cancer. Some women were additionally screened for STIs. We also aimed to establish an association between the presence of HPV and STI.
Methods: A total of 40 women aged 20-67 years participated in this study. Cervical and or vaginal swabs were collected in liquid-based cytology containers. The samples were tested for fourteen HPV genotypes by USFDA-approved Cobas HPV test. Out of these 40 women 26 were also tested for STI panel.
Results: All women participants were screened for hr-HPV. A total 65% of the study population underwent both the HPV test and the STI test. 7.5% of total women were positive for hrHPV. 30.76% of women tested positive for Ureaplasma and Gardnerella vaginalis in the STI panel. Some women also showed simultaneous presence of STI and HrHPV.
Conclusions: The results of this study will help in better and early diagnosis of women at risk of cervical cancer. The detection of HPV and STI present simultaneously can further help in establishing the role of these two conditions in the development of cervical cancer. Such studies are an encouragement to the HPV elimination programme and vaccination drive that has taken an impetus in recent times in India.
References
Chrysostomou AC, Kostrikis LG. Methodologies of primary HPV testing currently applied for cervical cancer screening. Life. 2020;10(11):290.
Rajaram S, Gupta B. Screening for cervical cancer: Choices & dilemmas. Ind J Medi Res. 2021;154(2):210-20.
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynecol Obstetr. 2021;155:28-44.
Ntanasis-Stathopoulos I, Kyriazoglou A, Liontos M, Dimopoulos M, Gavriatopoulou M. Current trends in the management and prevention of human papillomavirus (HPV) infection. J BUON. 2020;25(3):1281-5.
Mittal S, Banks L. Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation. Mutat Res Rev Mutat Res. 2017;772:23-35.
Alotaibi HJ, Almajhdi FN, Alsaleh AN, Obeid DA, Khayat HH, AlMuammer TA, et al. Association of Sexually Transmitted infections and human papillomavirus co-infection with abnormal cervical cytology among women in Saudi Arabia. Sau J Biol Sci. 2020;27(6):1587–95.
Shah UJ, Nasiruddin M, Dar SA, Khan MKA, Akhter MR, Singh N, et al. Emerging biomarkers and clinical significance of HPV genotyping in prevention and management of cervical cancer. Microbial pathogenesis. 2020;143:104131.
Flores-Miramontes MG, Olszewski D, Artaza-Irigaray C, Willemsen A, Bravo IG, Vallejo-Ruiz V, et al. Detection of alpha, beta, gamma, and unclassified human papillomaviruses in cervical cancer samples from mexican women. Front Cell Infect Microbiol. 2020;10:234.
Kops NL, Bessel M, Horvath JDC, Domingues C, de Souza FMA, Benzaken AS, et al. Factors associated with HPV and other self-reported STI coinfections among sexually active Brazilian young adults: crosssectional nationwide study. BMJ open. 2019;9(6):e027438.
Ma Z, Gharizadeh B, Cai X, Li M, Fellner MD, Basiletti JA, et al. A comprehensive HPV-STI NGS assay for detection of 29 HPV types and 14 non-HPV sexually transmitted infections. Infect Age Cancer. 2022;17(1):1-9.
Biernat-Sudolska M, Szostek S, Rojek-Zakrzewska D, Klimek M, Kosz-Vnenchak M. Concomitant infections with human papillomavirus and various mycoplasma and ureaplsasma species in women with abnormal cervical cytology. Advan Med Sci. 2011;56(2):299-303.
Zhang Z-F, Graham S, Yu S-Z, Marshall J, Zielezny M, Chen YX, et al. Trichomonas vaginalis and cervical cancer: a prospective study in China. Ann Epidemiol. 1995;5(4):325-32.
Scaglione E, Mantova G, Caturano V, Fanasca L, Carraturo F, Farina F, et al. Molecular epidemiology of genital infections in campania region: a retrospective study. Diagnos. 2022;12(8):1798.
Kechagia N, Bersimis S, Chatzipanagiotou S. Incidence and antimicrobial susceptibilities of genital mycoplasmas in outpatient women with clinical vaginitis in Athens, Greece. J Antimicro Chemoth. 2008;62(1):122-5.
Abou Chacra L, Fenollar F, Diop K. Bacterial vaginosis: what do we currently know? Front Cellu Infect Microbiol. 2022;11:1393.
Parthenis C, Panagopoulos P, Margari N, Kottaridi C, Spathis A, Pouliakis A, et al. The association between sexually transmitted infections, human papillomavirus, and cervical cytology abnormalities among women in Greece. Int J Infec Dis. 2018;73:72-7.
Kim YK, Lee DH, Lee CH, Jung YS, Youn C, Lee WK. Prevalence of human papillomavirus and bacteria as sexually transmitted infections in symptomatic and asymptomatic women. Clin Pract. 2017;14(6):397-401.
dos Santos LM, de Souza JD, Mbakwa HA, Nobre AFS, Vieira RC, Ferrari SF, et al. High prevalence of sexual infection by human papillomavirus and Chlamydia trachomatis in sexually-active women from a large city in the Amazon region of Brazil. PLoS ONE. 2022;17(7):e0270874.
